HC Wainwright Lowers Addex Therapeutics (NASDAQ:ADXN) to Neutral

Addex Therapeutics (NASDAQ:ADXNGet Rating) was downgraded by HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Thursday, The Fly reports.

Shares of Addex Therapeutics stock opened at $1.11 on Thursday. The stock has a market cap of $12.04 million, a price-to-earnings ratio of -0.34 and a beta of 1.60. The firm’s 50-day moving average is $3.89 and its 200 day moving average is $5.03. Addex Therapeutics has a 1 year low of $1.05 and a 1 year high of $10.90.

About Addex Therapeutics (Get Rating)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.

Featured Stories

The Fly logo

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.